RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge
Open Access
- 28 April 2022
- journal article
- research article
- Published by Elsevier BV in Translational Research
- Vol. 248, 11-21
- https://doi.org/10.1016/j.trsl.2022.04.007
Abstract
No abstract availableFunding Information
- National Institutes of Health (R01AI137472, R01AI139092, R01AI157975)
This publication has 55 references indexed in Scilit:
- SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccinesPublished by Cold Spring Harbor Laboratory ,2021
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020Morbidity and Mortality Weekly Report (MMWR), 2021
- Escape from neutralizing antibodies by SARS-CoV-2 spike protein variantseLife, 2020
- Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2Emerging Therapeutic Targets, 2020
- A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2Cell Research, 2020
- Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2Antiviral Research, 2020
- Structural basis of receptor recognition by SARS-CoV-2Nature, 2020
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccineCellular & Molecular Immunology, 2020
- Subunit Vaccines Against Emerging Pathogenic Human CoronavirusesFrontiers in Microbiology, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020